third generation glp 1 LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism GLP-1-based therapies for diabetes, obesity

Research shows that about 74% of women using spironolactone see improvement or stabilization in hair loss

In particular, long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) can cause gastric mucosal damage as they can inhibit mitochondrially encoded cytochrome C oxidase I (MT-CO1, also known as COX-1) and block its protective effect on gastric mucosa

The STEP 2 trial [2] , which included participants with type 2 diabetes, showed slightly more modest but still substantial results, with 9.6% average weight loss compared to 3.4% with placebo

What should you consider before starting GLP-1s for pregnancy

[DOI] [PubMed] [Google Scholar] 141.L F, Jin T, Drucker DJ